Desensitization in HLA-incompatible kidney recipients and survival.

  title={Desensitization in HLA-incompatible kidney recipients and survival.},
  author={Robert A. Montgomery and Bonnie E. Lonze and Karen Eileen King and Edward S. Kraus and Lauren M. Kucirka and Jayme E. Locke and Daniel S. Warren and Christopher E. Simpkins and Nabil N. Dagher and Andrew L. Singer and Andrea A. Zachary and Dorry L. Segev},
  journal={The New England journal of medicine},
  volume={365 4},
BACKGROUND More than 20,000 candidates for kidney transplantation in the United States are sensitized to HLA and may have a prolonged wait for a transplant, with a reduced transplantation rate and an increased rate of death. One solution is to perform live-donor renal transplantation after the depletion of donor-specific anti-HLA antibodies. Whether such antibody depletion results in a survival benefit as compared with waiting for an HLA-compatible kidney is unknown. METHODS We used a… 

Figures and Tables from this paper

HLA incompatible renal transplantation

A significant population of patients will not benefit from either kidney-paired donation or desensitization and will require a hybrid technique in which the goal of matching is to reduce the strength of the DSA to facilitate desensitized patients.

Desensitization Outcomes: Quantifying and Questioning

    E. ColeK. Tinckam
    Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2014
Reports which would target desensitizing centers have the potential to reduce transplant access for sensitized patients in those very centers providing this enhanced treatment, with the failure of the Center for Medicare andMedicaid studies to adjust for the anticipated reduction in graft survival when determining program-specific data.

Modern approaches to incompatible kidney transplantation.

Intravenous immunoglobulin (IVIG) remains the backbone of HLA desensitization therapy and has been shown in a prospective, randomized, placebo controlled trial to improve transplantation rates.

Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption

The desensitization protocol for pre-sensitized living donor kidney transplant recipients with DSA resulted in good graft outcomes with side effects and rejection rates similar to that of standard-risk recipients.

Outcome after Desensitization in HLA or ABO-Incompatible Kidney Transplant Recipients: A Single Center Experience

A favorable short-term allograft outcome in LDK transplant recipients after desensitization is demonstrated, however, the desensitized was associated with an increased risk of BKVN.

Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg)

    D. GlotzC. Antoine J. Bariéty
    Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2002
It is shown that administration of intravenous immunoglobulins (IVIg) can induce a profound and sustained decrease in the titers of anti‐HLA antibodies, which allows safe and prompt kidney transplantation of immunized patients.

ABO Incompatible Renal Transplantation: A Paradigm Ready for Broad Implementation

The findings of this study and the relatively simple therapeutic regimen used should facilitate widespread application of ABOi kidney transplants resulting in one of the most rapid escalations in access to organs in the modern era of kidney transplantation.

Renal Transplantation Across HLA and ABO Antibody Barriers: Integrating Paired Donation into Desensitization Protocols

    R. Montgomery
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2010
It is estimated that most patients with incompatible live donors can undergo successful renal transplantation, and KPD should be favored among patients with immunologic phenotypes that are likely to match without prolonged waiting times.

Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients

Plasmapheresis and low-dose CMV-Ig combined with traditional immunosuppression is effective in producing a specific and durable elimination of antibody to donor HLA.


This protocol shows promise for eliminating DSA preemptively among patients with low-titer positive antihuman globulin-enhanced, complement-dependent cytotoxicity cross-matches, allowing the successful transplantation of these patients using a live donor without any cases of HAR.

ABO Incompatible High‐Titer Renal Transplantation without Splenectomy or Anti‐CD20 Treatment

    D. SegevC. Simpkins R. Montgomery
    Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2005
It is hypothesized that plasmapheresis (PP) and low dose CMV hyper‐immunoglobulin (CMVIg) alone would be sufficient to achieve successful engraftment of ABOi kidneys and may limit the need for long‐term antibody suppression provided by splenectomy or anti‐CD20.

All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies

It is concluded that HLA antibodies may be a prerequisite for chronic immunologic rejection, and 29 consecutive cases of chronic rejection failures as much as one year before the loss of grafts were found.

A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody

It is concluded that multiple plasmapheresis‐based regimens leads to more reproducible desensitization and lower humoral rejection rates than a single high‐dose of IVIG, but that no regimen was completely effective in preventing humoral rejected.

Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.

Biochemical studies to determine the effective component of IVIG show that it is the IgG fraction and not soluble antigen or the minor IgM or IgA contaminants that is responsible, which suggests an antiidiotypic modulation of anti-HLA antibodies in vitro and in vivo.